SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  FORM
10-K  (Mark One) [x]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934   For the fiscal year ended December 31,
2007  OR  [
 ]
TRANSITION REPORT UNDER
SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF
1934   From the transition period from ___________
to ____________.  Commission File Number 000-51750  TRIPLE A MEDICAL, INC. (Exact
name of small business issuer as specified in its charter)  Nevada
                                                                                                                             20-4846807 (State or
other jurisdiction of incorporation or organization)
                           (IRS
Employer Identification No.)  604 Creekview, Ovilla, Texas
75154 (Address
of principal executive offices)  (800) 843-8179 (Issuer's
telephone number)  N/A (Former
name, former address and former fiscal year, if changed since last report)  Indicate
by check mark whether the registrant (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days:.
 Yes [ X ]   No [   ].  Large
Accelerated Filer [  ]

Accelerated
Filer [  ]Non-Accelerated
Filer [  ]

Smaller
Reporting Company [ X ]  Indicate by a check
mark whether the company is a shell company (as defined by Rule 12b-2 of the
Exchange Act:  Yes [   ]   No [X].    As of March 31, 2008,
there were 14,047,500 shares of Common Stock of the issuer outstanding.


TABLE OF CONTENTS  Page**PART I**Financial Statements

F-1ITEM 1.
Description of Business

1ITEM 2.
Description of Property

4ITEM 3.
Legal Proceedings

4ITEM 4.
Submission of Matters to a Vote
of Security Holders

4PART IIITEM 5.
Market for Registrants Common
Equity And Related Stockholders Matters

5ITEM 6.
Selected Financial Data.

5ITEM 7.
Managements Discussion and
Analysis of Financial Condition and Results of Operation.

5ITEM 7A.
Quantitative and Qualitative
Disclosures About Market Risk.

6ITEM 8.
Financial Statements and
Supplementary Data.

6ITEM 9.
Changes in and Disagreements
with Accountants on Accounting and Financial Disclosure.

7ITEM 9A.
Controls and Procedures.

7ITEM 9B.
Other Information.

8PART IIIITEM 10.
Directors, Executive Officers
and Corporate Governance.

9ITEM 11.
Executive Compensation.

9ITEM 12.
Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters

9ITEM 13.
Certain Relationships and
Related Transactions, and Director Independence

10ITEM 14.
Principal Accounting Fees and
Services.

10PART IVITEM 15.
Exhibits and Financial
Statement Schedules.

12EXHIBIT INDEX

12Exhibit 31.1
Certification of Chief
Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as
enacted by Section 302 of the Sarbanes-Oxley Act of 2002.Exhibit 31.2
Certification of Chief
Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as
enacted by Section 302 of the Sarbanes-Oxley Act of 2002.Exhibit 32.1
Certification of Chief
Executive Officer and Chief Financial Officer, pursuant to 18 United
States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley
Act of 2002.SIGNATURES

13  i           REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   To the Board of Directors Triple A Medical, Inc. Ovilla, Texas  We have audited the accompanying consolidated balance
sheets of Triple A Medical, Inc. , as of December 31, 2007 and 2006, and the
related consolidated statements of operations, changes in stockholders' equity,
and cash flows for the years then ended. These consolidated financial statements
are the responsibility of the management of Triple A Medical, Inc.  Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.  We conducted our audits in accordance with the standards
of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform an audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. Triple A Medical, Inc is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. Our
audits included consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of Triple
A Medical, Incs internal control over financial reporting. Accordingly, we
express no such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.  In our opinion, the financial statements referred to
above present fairly, in all material respects, the financial position of Triple
A Medical, Inc. as of December 31, 2007 and 2006, and the results of its
operations and its cash flows for the periods described in conformity with
accounting principles generally accepted in the United States of America.  The accompanying consolidated financial statements have
been prepared assuming that the Company will continue as a going concern. As
discussed in Note 2 to the financial statements, the Company has suffered
recurring losses from operations and has recurring deficits in cash flows form
operating activities, which raises substantial doubt about its ability to
continue as a going concern. Management's plans regarding these matters also are
described in Note 2. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.  /s/  Malone & Bailey, PC MALONE & BAILEY, PC www.malone-bailey.com Houston, Texas  March 31, 2008        F-1     TRIPLE A MEDICAL, INC.Consolidated Balance SheetsDecember 31, 2007 and 2006ASSETS



2007


2006Current
AssetsCash
and Cash Equivalents
$
270,906

$
265,728Other
receivables

1,100


-Prepaid
Expenses

29,363


-Total
Current Assets

301,369


265,728Computer
Equipment, net

23,270


-Developed
Software, net

362,549


379,322TOTAL
ASSETS
$
687,188

$
645,050LIABILITIES
AND STOCKHOLDERS' EQUITYCurrent
LiabilitiesAccounts
Payable and Accrued Expenses
$
67,756

$
32,996Total
Current Liabilities

67,756


32,996Commitments
and contingencies

-


-Stockholders'
EquityPreferred
stock, $0.01 par value, 20,000,000 authorized,-0-
 issued and outstanding

-


-Common
Stock, $.001 par value, 50,000,000 shares authorized,13,744,000
and 13,500,00 shares issued and outstanding, respectively
13,744


13,500Additional
Paid-In Capital

1,258,756


753,000Accumulated
 Deficit

(653,068)


(154,446)Total
Stockholders' Equity

619,432


612,054TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY
$
687,188

$
645,050See accompanying summary of accounting policies and notes to
consolidated financial statements.     F-2


TRIPLE A MEDICAL, INC.Consolidated Statements of OperationsYears Ended December 31, 2007 and 20062007


2006REVENUE


$
207,443

$
-OPERATING
EXPENSESDepreciation
and amortization

21,389


-Selling,
General & Administrative:

434,765


11,498Software
Development Costs

255,437


132,653TOTAL
OPERATING EXPENSES

711,591


144,151NET
LOSS FROM OPERATIONS

(504,148)


(144,151)OTHER
INCOMEInterest
income

5,526


3,205NET
LOSS


$
(498,622)

$
(140,946)Basic
and diluted weighted average shares outstanding

13,535,751


13,500,000Basic
and diluted net loss per share
$
(0.04)

$
(0.01)See accompanying summary of accounting policies and notes to
consolidated financial statements.


F-3       TRIPLE A MEDICAL, INC.Consolidted Statements of Stockholders'
EquityYears Ended December 31, 2007 and 2006Common Stock

Paid-In

AccumulatedShares

Amount

Capital

Deficit

TotalsBalance
at December 31, 2005
13,500,000
$
13,500
$
-
$
(13,500)

-Imputed
rent




8,000



8,000Contributed
capital




745,000



745,000Net
Loss






(140,946)

(140,946)Balance
at December 31, 2006
13,500,000

13,500

753,000

(154,446)

612,054Contributed
capital




376,000



376,000Imputed
rent




8,000



8,000Cash
received for stock
244,000

244

121,756



122,000Net
Loss






(498,622)

(498,622)Balance
at December 31, 2007
13,744,000
$
13,744
$
1,258,756
$
(653,068)
$
619,432See accompanying summary of accounting policies and notes to
consolidated financial statements.F-4


TRIPLE A MEDICAL, INC.Consolidated Statements of Cash FlowsYears Ended December 31, 2007 and 20062007

2006CASH
FLOWS FROM OPERATING ACTIVITIESNet
Loss


$
(498,622)
$
(140,946)Adjustments
to reconcile net income to net cashprovided
by operating activities:Depreciation
and amortization

21,389

-Imputed
rent

8,000

8,000Accounts
receivable - employee

(1,100)

-Prepaid
expenses

(29,363)

-Change
in Accounts Payable and Accrued Expenses

34,760

32,996Net
Cash Used in Operating Activities

(464,936)

(99,950)CASH
FLOWS FROM INVESTING ACTIVITIESSoftware
development costs

-

(379,322)Purchase
of fixed assets

(27,886)

-Net
Cash Used in Investing Activities

(27,886)

(379,322)CASH
FLOWS FROM FINANCING ACTIVITIESContributed
capital

376,000

745,000Proceeds
from Sale of Stock

122,000

-Net
Cash Provided by Financing Activities

498,000

745,000NET
INCREASE IN CASH AND CASH EQUIVALENTS

5,178

265,728CASH
AND CASH EQUIVALENTS AT BEGINNING OF YEAR

265,728

-CASH
AND CASH EQUIVALENTS AT END OF YEAR
$
270,906
$
265,728SUPPLEMENTAL
DISCLOSURESInterest
paid

$
-
$
-Income
taxes paid
$
-
$
-See accompanying summary of accounting policies and notes to
consolidated financial statements.      F-5     TRIPLE A MEDICAL, INC. Notes to the Consolidated Financial Statements December 31, 2007 and 2006   NOTE 1
 NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES  Nature of Activities, History and Organization:  Triple A Medical,
Inc. (Triple A), through its wholly owned subsidiary Triple A Software, Inc.
(TAS), has developed and is in the process of selling and distributing a
proprietary software developed for use as an electronic medical record by
orthopedic surgeons. Triple A is located in Ovilla, Texas and was incorporated
on December 27, 2006 in Nevada.  Triple A is the
parent company of TAS, a Texas corporation. TAS was established in 2005 and
since that time has been working to develop software. The software being
developed is designed as an easy to use, interactive software with customization
that can be made as it is used.  On December 29, 2006,
Triple A issued 13,500,000 shares of common stock in exchange for a 100% equity
interest in TAS. As a result of the share exchange, TAS became the wholly owned
subsidiary of Triple A. The share exchange was treated as a recapitalization of
TAS. The financial statements have been prepared as if TAS had always been the
reporting company and then on the share exchange date, had changed its name and
reorganized its capital stock.  Significant Accounting Policies  Use of Estimates  The preparation of
financial statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect certain
reported amounts and disclosures.  Accordingly, actual results could differ
from those estimates.  Cash and Cash
Equivalents  All highly liquid
investments with original maturities of three months or less are stated at cost
which approximates market value.  Property and
Equipment  Property and
equipment are carried at the cost of acquisition or construction and depreciated
over the estimated useful lives of the assets. Costs associated with repair and
maintenance are expensed as incurred. Costs associated with improvements which
extend the life, increase the capacity or improve the efficiency of our property
and equipment are capitalized and depreciated over the remaining life of the
related asset. Gains and losses on dispositions of equipment are reflected in
operations. Depreciation is     F-6  provided
using the straight-line method over the estimated useful lives of the assets,
which is 3 years.  Software
Development Costs  Triple A follows
Statement of Financial Accounting Standards 86, Accounting for the costs of
computer software to Be Sold, Leased, or Otherwise Marketed.  In
accordance with SFAS 86, internal costs incurred to create computer software are
charged to expense when incurred until technological feasibility has been
established for the product. Technological feasibility is established upon
completion of a detailed program design or, in its absence, completion of a
working model. After technological feasibility is established, the costs of
coding and testing and other costs of producing product masters are capitalized.
Cost capitalization ceases when the product is available for general release to
customers.  Capitalized software
costs are amortized on a product-by-product basis, starting when the product is
available for general release to customers. Annual amortization is the greater
of straight-line over the product's estimated useful life or the percent of the
product's current-year revenues as compared to the product's anticipated future
revenues.  Capitalized software
costs are evaluated for impairment on a product-by-product basis by a comparison
of the unamortized capitalized costs to the product's net realizable value. The
amount by which the unamortized capitalized costs exceed the net realizable
value is recognized as an impairment charge.  Revenue
Recognition  Triple A recognizes
revenue when software is sold, delivery has occurred, the sales price is fixed
or determinable and collectibility is probable. Triple A recognizes revenue from
installation and other services as the services are performed.  Income
Taxes  Income taxes are
computed using the asset and liability method.  Under the asset and
liability method, deferred income tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets
and liabilities and are measured using the currently enacted tax rates and laws.
 A valuation allowance is provided for the amount of deferred tax assets
that, based on available evidence, are not expected to be realized.  Earnings (Loss)
per Share  Earnings (loss) per
share (basic) is calculated by dividing the net income (loss) by the weighted
average number of common shares outstanding for the period covered.  As
Triple A has no potentially dilutive securities, fully diluted earnings (loss)
per share is identical to earnings (loss) per share (basic).  NOTE 2 - GOING
CONCERN  Triple A 's financial
statements have been presented on the basis that it is a going concern, which
contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business.     F-7    Triple A has suffered
recurring losses since inception and accumulated a deficit of $653,068 as of
December 31, 2007. Additionally, Triple A has incurred recurring deficits in
cash flows from operating activities.  Triple A 's ability
to continue as a going concern is dependent upon its ability to complete the
development of its developed software product with existing sources of capital,
to successfully market and implement its developed software product and to
achieve profitable operations.  The accompanying financial statements do
not include any adjustments that might result from the outcome of these
uncertainties.  NOTE 3 -
CONCENTRATIONS  Triple A maintains
demand deposit accounts which at times exceed FDIC insurance limitations of
$100,000 per account. Balances on deposit at financial institutions as of
December 31, 2007 in excess of FDIC deposit insurance amounts were $170,906.  NOTE 4 - PROPERTY
AND EQUIPMENT  Property and
equipment consisted of the following at December 31, 2007 and 2006:   Description

Life

2007
Amount

2006
AmountComputer
equipment

3 years

$24,639

$        0Accumulated
depreciation



(1,369)

0$23,270

$
       0  Depreciation expense
totaled $1,369 and $0 in 2007 and 2006, respectively.   NOTE 5 
CAPITALIZED SOFTWARE DEVELOPMENT COSTS  Capitalized software
development costs at December 31, 2007 and 2006 consist of the following:  2007

2006Software

$382,569

$379,322Less:
accumulated amortization

(20,020)

(0)$362,549

$379,322   Amortization expense
totaled $20,020 and $0 in 2007 and 2006, respectively  $132,653 of software
development costs was expensed during 2006 and $255,437 in 2007.      F-8  NOTE
6  INCOME TAXES  Deferred tax assets at December 31, 2007 and 2006 consisted of the
following:  Year ended December 31, 2007
Year ended December 31, 2006Net operating loss carryforward
$
   222,043
$
    52,512Less: valuation allowance
(222,043)
(52,512)Net deferred tax asset
-
-  The net deferred tax
asset generated by the loss carry-forward has been fully reserved.  The
cumulative net operating loss carry-forward is approximately $653,000 at
December 31, 2007, and will expire in the years 2024 through 2027.  The
difference in the income tax benefit not shown in the consolidated statements of
operations and the amount at that  would  result  if  the
U.S. Federal statutory rate  of  34%  were  applied to
pre-tax loss for 2007 and 2006 is attributable to the valuation allowance.  The realization of
deferred tax benefits is contingent upon future earnings.   NOTE 7  RELATED
PARTY TRANSACTIONS  In order to fund the
development of the software, Triple A entered into  an Investment and Net
Revenue Agreement with Phoenix Ortho, LLC (ORTHO), an entity controlled by a
relative of the President of Triple A. In connection with this agreement ORTHO
provided Triple A $745,000 during 2006 and $376,000 in 2007. This cash is
reflected as additional paid-in capital as of December 31, 2006 and 2007. In
exchange for this contributed capital, Triple A provided ORTHO with an income
participation interest in its operations. The terms of this agreement require
Triple A to pay ORTHO 32.60% of the net income generated by the business in the
immediately preceding month.  In addition, office
space has been contributed by related parties since April 2006 rent-free.
 $8,000 per year of expense has been imputed related to this office
space.  NOTE 8  MAJOR
CUSTOMERS  Revenues had two
customers that consisted of 93% of revenues for 2007. There were no major
customers in 2006.  NOTE 9 
SUBSEQUENT EVENTS  In 2007 the Company
had filed a Form SB-1 with the U.S. Securities & Exchange Commission which
became effective in July 2007. Under the Form SB-1, the Company filed to offer a
minimum of $75,000     F-9    and a maximum of
$500,000. In March 2008, the Company  raised a total amount of $258,750 of
which 136,750 was raised after December 31, 2007.      F-10  PART
I.  ITEM
1. DESCRIPTION
OF BUSINESS  This report
contains forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities Exchange
Act of 1934, as amended. The Companys actual results could differ materially
from those set forth on the forward looking statements as a result of the risks
set forth in the Companys filings with the Securities and Exchange Commission,
general economic conditions, and changes in the assumptions used in making such
forward looking statements.  General  The
company was founded to create electronic healthcare software applications.
 The initial development is an Electronic Health Record (EHR), specifically
designed to meet the needs of orthopedic physicians. For the past 4 years, our
President has worked directly with dozens of orthopedic physicians in more than
40 states. He has reviewed orthopedic clinical research and extensively surveyed
reference materials. Based upon the research, Mr. McCune created a database with
a graphical interface to assist orthopedic physicians with the documentation of
the patient encounter.  The Market  Phoenix
Ortho is participating in an $18 billion market for Electronic Health Records
(EHR). The Orthopedics market approaches $2 billion. There are more than 20,500
board certified orthopedists and 12,872 orthopedic group practices. Research
indicates that this market is less than 10% penetrated.  Recent surveys
indicate that 58% of medical practices are looking at purchasing an EHR in the
next 2 years. In 2005 the average orthopedic EHR sale was $171,000. (2001 AAOS
Census, 2004 MGMA Survey) Recent growth rate in new sales has averaged about
30%. We expected this growth rate will accelerate sharply over the next two
years.  Keys to
Success  Focus: We believe focus is the essential ingredient to
successful EHR development and deployment. Phoenix Ortho is unique in our
extensive experience and singular focus on orthopedics. By focusing on one
specialty, we can avoid the wholesale generalities that have plagued EHR vendors
and frustrated their orthopedic clients. Phoenix Ortho understands the unique
requirements of orthopedic physicians. Focus promotes the creation of relevant
content and specialty specific application functionality. Content relevance is a
significant factor in physician adoption.  In
November of 2005, we began the development of a new orthopedic EHR. The
new project was focused on resolving the key problems that have historically
posed barriers to adoption, successful implementation and client satisfaction.
These obstacles can be grouped together in four categories; Product
Functionality, Product Implementation, Product Support, Product Acquisition
Cost.  Product Functionality:The software will establishnew standards for ease of use, efficiency, stability and availability
facilitating end user adoption. The software is designed and scaled specifically
for the pen     1    tablet
environment. We believe the pen tablet is the device of choice for EHR end
users. Our development will utilize input tools such as sliders, combo boxes,
role over images and other custom designed tools to provide a truly keyboard
free interface. Other tablet input options such as Pen and Ink and Voice to
Text will be available as needed to capture representative content. The
ODClient will improve stability, performance and availability by utilizing .NET
automatic versioning and auto recovery from deadlock errors and memory leaks.
Advanced compilation and caching techniques substantially lower CPU utilization.
The ODClient (smart client) will support both disconnected and low bandwidth
clients supporting end user mobility and minimizing the frustration of Systems
down.  Product Implementation: We have developed an orthopedic,
client focused implementation methodology we call the AAA implementation plan.
This plan focuses on the three critical aspects of implementation; Assessment,
Adoption and Adaptation. All implementations will begin with Assessment. During
the assessment phase the unique needs of the end users are identified. Each user
is profiled to determine their needs and potential road blocks to success. The
physicians are identified as Champions, Contenders or Challengers. An
implementation strategy is designed around these Adoption Profiles.  The
Champions are the eager adopters and should be the first users. The Contenders
are frequently indifferent but, usually agreeable adopters.  The
Challengers represent approximately 30% of the physicians who will resist
implementation for a variety of reasons. Sometimes they feel they are too
technology challenged and fearful, some are too busy and may fear loss of
revenue by adoption, while others are just resistant to anything new. When these
objections are clearly understood, Adaptation can take place and in most cases
mitigate the Challengers objection(s). Adaptation is the process of introducing
(training) the end users to the application Best Practices. It also takes into
account the Profile of the end user to create a Best Practices by provider
(See Challengers above).  Product Support:The ODClient on the .NET framework makes
it easier than ever to update and deploy new applications. Thanks to
intelligent, one touch updates and intelligent support client PCs can be updated
by copying the application to the target directory.  Client PCs may be
updated automatically with no interruption or the may be updated on demand.  Product Acquisition Cost:Wewill provide
alternative acquisition models to help overcome purchase resistance due to
capital costs. Although we will make the EHR software available on the
traditional for purchase basis, through our innovative 3-Tier ODClient
architecture we will also offer a service based model. Our customers will be
able to utilize the full function and features of the EHR software for an
affordable monthly service charge.  Utilizing their
extensive experience and knowledge of orthopedics, coupled with state of the art
rapid development tools, we  believe these obstacles can be overcome and
their goals are achievable. The recent completion of their fully functional
prototype, suggests that their development strategies are on track.  Technology
Overview  For
many technologists and software developers, 2006 is a watershed year. With the
official release of Visual Studio 2005, providing a seamless integration between
C#, the .Net Framework 2.0 and SQL Server 2005, a  new  paradigm 
for software  development  has arrived.   According
 to  Bill Gates  the     2  transition to .NET is as dramatic as the move from MS-DOS to
Windows.  The emergence of these companion technologies has created an
opportunity for rapid development, application flexibility, architectural
mobility, simplified deployment and support/updates that did not exist prior to
November 2005.  We are
positioned to take full advantage of this shifting technological paradigm. The
software will be the first orthopedic EHR to be developed utilizing innovative
3-Tier architecture on SQL 2005, the .NET framework, C#, Visual Studio 2005 and
the Microsoft Enterprise Library.  Implementation of
3-Tier Architecture  ODClient:Combines the best of traditional rich client
functionality with the ease of thin client deployment and maintenance. ODClient
raises the standard by adding support for mobile, offline or low bandwidth users
with intelligent connection management (data caching and batch requests). Even
fully connected clients will see performance and stability benefits. ODClient
will reduce management costs by avoiding the complexities and application
fragility of traditional rich client deployments (shared code, registered
components, and DLLs in a common folder). ODClient will utilize a seamless,
simplified, predictable no touch deployment. Updates may occur in the
background or on demand. Tools: Visual C# 2005, Microsoft Office 2003, XML
underlying structure.  Application Server Tier:Business-objects that implement
the business rules reside here. This tier isolates the data from direct access
by the clients. Tools: .Net Framework 2.0, Microsoft Enterprise Library.  Data
Server Tier: This tier is responsible for data storage. SQL Server 2005 with
..NET integration is the database of choice. However, the 3-Tier architecture
supports application portability and database independence. Tools: SQL Server
2005, T-SQL, CLR Execution Environment, .Net Code Integration, Business
Intelligence, Indexed, Full Text Search.  Mission  We will
develop, document and market EHR solutions that are efficient, intuitive, easy
to use, and promote physician acceptance.  This software will reduce the
cost and risks associated with manual paper based systems. This will in turn
improve the quality of care by more completely documenting patient care,
eliminating common errors and tracking relevant procedures, events and outcomes.
The EHR will provide an excellent ROI to the physician by reducing costs and
enhancing revenues do to improved documentation and optimal billable code
levels.  Conclusion  The
orthopedic EHR market is emerging rapidly with nearly $2 billion in potential
sales. We believe that our software is uniquely positioned to fill a substantial
void in the orthopedic vertical market for EHR.Our extensive orthopedic
experience, our singular focus, our dedicated, proactive approach to training,
implementation and support, coupled with our utilization of state of the art
development tools will distinguish us from every alternative EHR in the
orthopedic vertical market space. The result will be a     3    uniquely relevant orthopedic encounter management solution that is
efficient, intuitive, easy to use, and promotes physician acceptance. We expect
this EHR to be well received, quickly adopted, and widely endorsed by the
orthopedic community.     ITEM
2. DESCRIPTION
OF PROPERTY  Our corporate
facilities are located in a 1,200 sf office facility at 604 Creekview, Ovilla,
Texas 75154. The space is being contributed to the company until it has
sufficient revenues to commit to a permanent location.  ITEM
3. LEGAL
PROCEEDINGS  We are not involved
in any legal proceedings at this time.  ITEM
4. SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS  The registrant did
not submit any matters to its security holders for a vote.      4   PART II  ITEM
5. MARKET
FOR REGISTRANTS COMMON EQUITY AND RELATED STOCKHOLDERS MATTERS  The
Common Stock was not quoted on any exchange or quoted price medium. Subsequent
to year end, the Company started trading on the OTCBB under the ticker symbol
TAAA.  Shareholders As of
December 31, 2007, there were 139 record holders of the Common Stock.  Dividends The
Company has not paid dividends on any class of common equity since formation and
the Company does not anticipate paying any dividends on its outstanding common
stock in the foreseeable future.  Warrants The
Company has no warrants outstanding.   ITEM 6. SELECTED FINANCIAL DATA  Not
required   ITEM
7. MANAGEMENTS
DISCUSSION AND ANALYSIS OR PLAN OF OPERATION  Results for the
fiscal year ended December 31, 2007  At the
end of the first quarter of 2007, our software became operational and we started
marketing it by attending trade shows, print advertising and brochures and
personal contacts.  In August we had our first sale and installation of the
software which took us out of the development stage and into the operating phase
of our business. Our sales leads continue to be followed up on as we receive
them from our own efforts by attendance at trade shows and from referrals from
our industry cross marketing agreements.  REVENUE.  Revenue for the year ended December 31, 2007 was
$207,443 compared to zero revenues in 2006 since 2007 was our first year where
we had sales of our software; in 2006 we were still developing our software.  EXPENSES. Total expenses the twelve months ended December 31, 2007
was $711,591 compared to $144,151 for the year of 2006. In 2007, the three main
components of that expense were software development costs, depreciation and
amortization, and general and administrative expenses. Software     5    development costs are the amounts expended on our software after
it reached the point of being operational. These amounts for the twelve months
ended December 31, 2007 were $255,437 compared to $132,653 for the same period
in 2006.  We had no
depreciation or amortization in 2006 but recorded $21,389 in 2007.  In
2007, we had selling, general and administrative expenses of $434,765 compared
with $11,498 in 2006. The significant increase is due to our change from a
company that was just developing software to a company that had a software
product and was marketing and installing it. In order to do this, we had to
incur costs for administration, service and support.  OTHER
INCOME . We had interest income of $5,526 in 2007 compared with $3,205 in 2006.
The increase was due to the greater cash balances the company had during the
year.  NET
LOSS. Net loss for the year ended December 31, 2007 was $498,622 compared with a
loss of $140,946 for the year of 2006. The losses in both years was due to our
company developing software and only started selling in the last part of
2007.  LIQUIDITY AND CAPITAL RESOURCES. Our cash balance at December 31,
2007 was $270,906. We filed a Form SB-1 in 2007 and when we closed the offering
in March 2008, we had raised a total of $258,750. Our sales efforts are
materializing into sales and with the cash we have in the bank and the revenue
we are starting to see from sales, we believe we have enough liquidity to carry
us to the point where ales of our software provide enough cash flow to
internally fund our operations.  Employees  As of December 31,
2007, the Company had three employees.   ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK  Not
applicable   ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA  Incorporated in this filing are the following financial
statements:  Report of Independent Registered
Public Accounting Firm Consolidated Balance Sheets at
December 31, 2007 and 2006 Consolidated Statements of Operations
for the years ended December 31, 2007 and 2006 Consolidated Statements of
Stockholders Equity for the years ended December 31, 2007 and 2006 Consolidated Statements of Cash Flows
for the years ended December 31, 2007 and 2006     6  Notes to
the Financial Statements  ITEM
9. CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE  We have
retained Malone & Bailey, PC as our registered independent public accounting
firm. We have had no
disagreements with them on accounting and disclosure issues.   ITEM
9A. CONTROLS
AND PROCEDURES  Evaluation of
Disclosure Controls and Procedures Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required
to be disclosed by an issuer in the reports that it files or submits under the
Securities Exchange Act of 1934, as amended (the "Act") is accumulated and
communicated to the issuer's management, including its principal executive and
principal financial officers, or persons performing similar functions, as
appropriate to allow timely decisions regarding required disclosure. It should
be noted that the design of any system of controls is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance
that any design will succeed in achieving its stated goals under all potential
future conditions, regardless of how remote.  As of the end of the period
covered by this Annual Report, we carried out an evaluation, under the
supervision and with the participation of our President, also serving as our
Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures.  Based on this evaluation, our
President has concluded that the Companys disclosure controls and procedures
are not effective because of the identification of a material weakness in our
internal control over financial reporting which is identified below, which we
view as an integral part of our disclosure controls and procedures.  Changes in
Internal Controls over Financial Reporting  We have
not yet made any changes in our internal controls over financial reporting that
occurred during the period covered by this report on Form 10-K that has
materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.  Managements
Annual Report on Internal Control Over Financial Reporting  Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting, as such term is defined in
Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control
system was designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes, in accordance with generally accepted accounting principles. Because
of inherent limitations, a system of internal control over financial reporting
may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate due to change in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.      7    Our
management conducted an evaluation of the effectiveness of our internal control
over financial reporting using the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO) in Internal
ControlIntegrated Framework. Based on its evaluation, our management concluded
that there is a material weakness in our internal control over financial
reporting. A material weakness is a deficiency, or a combination of control
deficiencies, in internal control over financial reporting such that there is a
reasonable possibility that a material misstatement of the Companys annual or
interim financial statements will not be prevented or detected on a timely
basis.  The
material weakness relates to the lack of segregation of duties in financial
reporting, as our financial reporting and all accounting functions are performed
by external accountants who may not always get full information and therefore
something is not recorded appropriately.  Our President does not possess
accounting expertise and our company does not have an audit committee. 
This weakness is due to the companys lack of working capital to hire additional
staff.  To remedy this material weakness, we intend to engage another
accountant to assist with financial reporting as soon as our finances will
allow.  This
annual report does not include an attestation report of the Companys registered
public accounting firm regarding internal control over financial
reporting.  Managements report was not subject to the attestation by the
Companys registered public accounting firm pursuant to temporary rules of the
SEC that permit the Company to provide only managements report in this annual
report.  The
Companys management carried out an assessment of the effectiveness of the
Companys internal control over financial reporting as of December 31, 2007. The
Companys management based its evaluation on criteria set forth in the framework
in Internal ControlIntegrated Framework issued by the Committee of Sponsoring
Organizations of theTreadway Commission. Based on that assessment, management
has concluded that the Companys internal control over financial reporting was
not effective as of December 31, 2007.   ITEM
9B. OTHER
INFORMATION  The
Registrant filed Form 8-K on December 18, 2007 to announced that in accordance
with its Form SB-1 which became effective on July 6, 2007, we raised at least
our minimum amount by the date of the end of the offering.     8  PART III  ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE  The directors and
officers of the company, their ages and principal positions are as follows:  P.
Morgan McCune 29 Director,
President; Secretary and Director Since
December 2006  Background of
Directors and Executive Officers:  P. Morgan McCune. AA
Degree Dallas Art Institute, Multimedia, Animation, Web Design, Web Developer,
Graphic Artist, Medical Illustrator 6 years experience, Co-developer NextGen
Orthopedic DB Developer NextGen Physical Therapy DB, Medical Illustrator for
NextGen EMR, Development Proficiency: SQL 2005, Visual Studio 2005, .NET, C#,
VB.  The
Registrant has one shareholder, the President, P. Morgan McCune, who owns at
least ten percent of the Companys common stock. The initial Form 3 required to
be filed by the shareholder was filed late. P. Morgan McCune was not required to
file a Form 4 or Form 5 as his share holdings did not change.   ITEM
11. EXECUTIVE
COMPENSATION  Our sole officer and
director received the following compensation for the years of 2004 and 2005. He
has no employment contract with the company.  Name
of Person Capacity
in which he served Aggregate Receiving
compensation to
receive remuneration remuneration P.
Morgan McCune President,
Secretary 2007
- $72,000 and
Treasurer 2006
- $0  As of the date of
this offering, our sole officer is our only employee. We have no employment
agreements with any officer, director or employee.   ITEM 12.
     SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS  The following table lists the officers, directors and stockholders
who, at the date hereof, own of record or beneficially, directly or indirectly,
more than 10% of the outstanding common stock, and all officers and directors of
the company:      9    Amount Owned Title
/ relationship Before
the to
Issuer Name
of Owner offering
        Percent  President,
Secretary and
Director P.
Morgan McCune 13,000,000
      94.59%  All officers and Directors
as a group 13,000,000
      94.59%   No options, warrants
or rights have been issued by the Company.   ITEM
13. CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE  In
December 2006, we exchanged 13,500,000 shares of common stock for 100% of the
outstanding stock of Triple A Software, Inc. In this transaction, the president
of the company received 13,000,000 shares of common stock in consideration for
his ownership in TAS.  As of
the date of this filing, there are no other agreements or proposed transactions,
whether direct or indirect, with anyone, but more particularly with any of the
following:  · a
director or officer of the issuer; · any
principal security holder; · any
promoter of the issuer; · any
relative or spouse, or relative of such spouse, of the above referenced
persons.   ITEM
14. PRINCIPAL
ACCOUNTING FEES AND SERVICES  (1) Audit fees  The
aggregate fees billed for professional services rendered by our auditors, for
the audit of the registrant's annual financial statements and review of the
financial statements included in the registrant's Form 10-K or services that are
normally provided by the accountant in connection with statutory and regulatory
filings or engagements for fiscal years 2007, the first year of audit, was
$15,163.  (2) Audit-related
fees      10  None  (3) Tax fees  None  (4) All other
fees  None  (5) Audit committee
policies and procedures  The Company does not
have an audit committee.  (6) If
greater than 50 percent, disclose the percentage of hours expended on the
principal accountant's engagement to audit the registrant's financial statements
for the most recent fiscal year that were attributed to work performed by
persons other than the principal accountant's full-time, permanent
employees.  Not applicable.    `     11    PART IV  ITEM
15. EXHIBITS,
FINANCIAL STATEMENT SCHEDULES  a) 1. Financial
Statements  Triple A Medical, Inc. and Subsidiaries  The following are contained in this
2007 Form 10-K report:  Report of Independent Registered
Public Accounting Firm  Consolidated Balance Sheets at
December 31, 2007 and 2006  Consolidated Statements of Operations
for the years ended December 31, 2007 and 2006  Consolidated Statements of
Stockholders Equity for the years ended December 31, 2007 and 2006  Consolidated Statements of Cash Flows
for the years ended December 31, 2007 and 2006  Notes to the Financial Statements   a) 3. Exhibits  Exhibits  Exhibit
Number Name of
Exhibit  31.1 Certification of
Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as
enacted by Section 302 of the Sarbanes-Oxley Act of 2002.  31.2 Certification of
Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as
enacted by Section 302 of the Sarbanes-Oxley Act of 2002.  32.1 Certification of
Chief Executive Officer and Chief Financial Officer, pursuant to 18 United
States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of
2002.              12   SIGNATURES  In
accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.  TRIPLE A MEDICAL,
INC.  By:  /s/
 P. Morgan McCune P. Morgan McCune,
President, CFO  Date: April 6,
2008      13